[PDF][PDF] Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig, SM Geyer, I Ghobrial, DJ Inwards… - J Clin Oncol, 2005 - academia.edu
J Clin Oncol, 2005•academia.edu
Purpose Mantle cell lymphoma (MCL) is characterized by at (11; 14) resulting in
overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus
(previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase
that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.
overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus
(previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase
that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.
Purpose
Mantle cell lymphoma (MCL) is characterized by at (11; 14) resulting in overexpression of cyclin D1 messenger RNA. This study tested whether temsirolimus (previously known as CCI-779), an inhibitor of the mammalian target of rapamycin kinase that regulates cyclin D1 translation, could produce tumor responses in patients with MCL.
academia.edu